Clinical importance of the CYP2C19*17 variant allele for voriconazole

類似資料

• High metabolic N-oxidation of voriconazole in a patient with refractory aspergillosis and CYP2C19*17/*17 genotype
  著者:: Bennis, Youssef, 等
  出版事項: (2015)
• Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19*17
  著者:: Li-Wan-Po, Alain, 等
  出版事項: (2010)
• Reply to “What Types of Candida Infections Should Be Included When Evaluating Breakthrough Infections during Posaconazole Prophylaxis?”
  著者:: Dolton, Michael J., 等
  出版事項: (2013)
• Safety of Voriconazole in a Patient with CYP2C9*2/CYP2C9*2 Genotype
  著者:: Geist, Marcus J.P., 等
  出版事項: (2006)
• Frequencies of clinically important CYP2C19 and CYP2D6 alleles are graded across Europe
  著者:: Petrović, Jelena, 等
  出版事項: (2019)